Restoration of MAGI-1 expression in human papillomavirus-positive tumor cells induces cell growth arrest and apoptosis

Journal of Virology

Volumn 88, Issue 13, 2014, Pages 7155-7169

  Kranjec, Christian ^a,b   Massimi, Paola ^a   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PDZ PROTEIN; PDZ1 PROTEIN; PROTEIN E6; PROTEIN MAGI 1; PROTEIN ZO1; PROTEINASE ACTIVATED RECEPTOR 3; UNCLASSIFIED DRUG; VIRUS PROTEIN; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; MAGI1 PROTEIN, HUMAN; NERVE CELL ADHESION MOLECULE; ONCOPROTEIN; PROTEIN BINDING; REPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; EMBRYO; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MUTAGENESIS; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TIGHT JUNCTION; TUMOR CELL; AMINO ACID SEQUENCE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; IMMUNOPRECIPITATION; METABOLISM; MOLECULAR GENETICS; MUTATION; PAPILLOMAVIRIDAE; PHYSIOLOGY; PROTEIN DEGRADATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION MOLECULES, NEURONAL; CELL PROLIFERATION; DNA-BINDING PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PDZ DOMAINS; PROTEIN BINDING; PROTEOLYSIS; REPRESSOR PROTEINS;

EID: 84901999767     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03247-13     Document Type: Article

References (63)

1. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, Zur Hausen H.2004. Classification of papillomaviruses. Virology 324:17-27. http://dx .doi.org/10.1016/j.virol.2004.03.033.
2. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen H Zur, de Villiers E-M. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79. http://dx.doi.org/10.1016/j.virol.2010.02.002.
3. zur Hausen H. 2009. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384:260-265. http://dx.doi.org /10.1016/j.virol.2008.11.046.
4. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT.1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905-3910.
5. Griep AE, Herber R, Jeon S, Lohse JK, Dubielzig RR, Lambert PF. 1993. Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol. 67:1373-1384.
6. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. 1993. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 90:5583-5587. http://dx.doi.org/10.1073/pnas.90.12 .5583.
7. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, Yamato K. 2003. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. 8:762-768. http://dx.doi.org/10.1016/j.ymthe.2003.08.004.
8. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS. 2008. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol. Oncol. 111:356-364. http://dx.doi.org /10.1016/j.ygyno.2008.06.033.
9. Qi Z, Xu X, Zhang B, Li Y, Liu J, Chen S, Chen G, Huo X. 2010. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells. Biochem. Cell Biol. 88:697-704. http://dx.doi.org/10.1139 /O10-005.
10. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA. 2012. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol. Cell Biol. 90:187-196. http://dx.doi.org/10.1038/icb.2011.19.
11. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79. http: //dx.doi.org/10.1126/science.2157286.
12. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136. http://dx.doi.org/10 .1016/0092-8674(90)90409-8.
13. Dyson N, Howley PM, Münger K, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. http://dx.doi.org/10.1126/science.2537532.
14. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620-4624.
15. Helt A-M, Funk JO, Galloway DA. 2002. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J. Virol. 76:10559-10568. http://dx.doi.org/10.1128/JVI.76 .20.10559-10568.2002.
16. Klingelhutz AJ, Foster SA, Mcdougall JK. 1996. Telomerase activation by the E6 gene-product of human papillomavirus type-16. Nature 380:79-82. http://dx.doi.org/10.1038/380079a0.
17. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M.1997. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94:11612-11616. http://dx.doi.org/10 .1073/pnas.94.21.11612.
18. Gardiol D, Kühne C, Glaunsinger B, Lee SS, Javier R, Banks L. 1999. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18: 5487-5496. http://dx.doi.org/10.1038/sj.onc.1202920.
19. Nakagawa S, Huibregtse JM. 2000. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20:8244-8253. http://dx.doi.org/10.1128/MCB.20.21.8244-8253.2000.
20. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. 2000. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and highrisk papillomavirus E6 oncoproteins. Oncogene 19:5270-5280. http://dx .doi.org/10.1038/sj.onc.1203906.
21. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, Banks L. 2002. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21:5088-5096. http: //dx.doi.org/10.1038/sj.onc.1205668.
22. Lee C, Laimins LA. 2004. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis ofhumanpapillomavirus type 31. J. Virol. 78:12366-12377. http://dx.doi.org/10.1128/JVI.78.22.12366-12377.2004.
23. Delury CP, Marsh EK, James CD, Boon SS, Banks L, Knight GL, Roberts S. 2013. The role of protein kinase A regulation of the E6 PDZbinding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J. Virol. 87:9463-9472. http://dx.doi.org/10.1128 /JVI.01234-13.
24. Watson RA, Thomas M, Banks L, Roberts S. 2003. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J. Cell Sci. 116:4925-4934. http://dx.doi.org/10.1242/jcs.00809.
25. Shai A, Brake T, Somoza C, Lambert PF. 2007. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 67:1626-1635. http://dx.doi.org/10.1158/0008-5472.CAN-06-3344.
26. Kranjec C, Banks L. 2011. A systematic analysis of human papillomavirus (HPV) E6PDZsubstrates identifies MAGI-1 as a major target ofHPVtype 16 (HPV-16) andHPV-18whose loss accompanies disruption of tight junctions. J. Virol. 85:1757-1764. http://dx.doi.org/10.1128/JVI.01756-10.
27. Woods DF, Bryant PJ. 1991. The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell 66:451-464. http://dx.doi.org/10.1016/0092-8674(81)90009-X.
28. Anderson JM. 1996. Cell signalling: MAGUK magic. Curr. Biol. 6:382-384. http://dx.doi.org/10.1016/S0960-9822(02)00501-8.
29. Dobrosotskaya I, Guy RK, James GL. 1997. MAGI-1, a membraneassociated guanylate kinase with a unique arrangement of protein-protein interaction domains. J. Biol. Chem. 272:31589-31597. http://dx.doi.org /10.1074/jbc.272.50.31589.
30. Thomas M, Glaunsinger B, Pim D, Javier R, Banks L. 2001. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 20:5431-5439. http://dx.doi.org/10.1038/sj.onc.1204719.
31. Thomas M, Massimi P, Navarro C, Borg J-P, Banks L. 2005. The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24:6222-6230. http://dx.doi .org/10.1038/sj.onc.1208757.
32. Fournane S, Charbonnier S, Chapelle A, Kieffer B, Orfanoudakis G, Travé G, Masson M, Nominé Y. 2011. Surface plasmon resonance analysis of the binding of high-risk mucosalHPVE6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1. J. Mol. Recognit. 24:511-523. http://dx.doi.org/10.1002/jmr.1056.
33. Dobrosotskaya IY, James GL. 2000. MAGI-1 interacts with beta-catenin and is associated with cell-cell adhesion structures. Biochem. Biophys. Res. Commun. 270:903-909. http://dx.doi.org/10.1006/bbrc.2000.2471.
34. Dobrosotskaya IY. 2001. Identification of mNET1 as a candidate ligand for the first PDZ domain of MAGI-1. Biochem. Biophys. Res. Commun. 283:969-975. http://dx.doi.org/10.1006/bbrc.2001.4880.
35. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E. 2005. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J. 19:115-117. http://dx.doi.org/10.1096/fj.04-1942fje.
36. Pim D, Storey A, Thomas M, Massimi P, Banks L. 1994. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9:1869-1876.
37. Pim D, Thomas M, Javier R, Gardiol D, Banks L. 2000. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 19:719-725. http://dx.doi.org/10.1038 /sj.onc.1203374.
38. García-Mata R, Dubash AD, Sharek L, Carr HS, Frost JA, Burridge K.2007. The nuclear RhoA exchange factor Net1 interacts with proteins of the Dlg family, affects their localization, and influences their tumor suppressor activity. Mol. Cell. Biol. 27:8683-8697. http://dx.doi.org/10.1128 /MCB.00157-07.
39. Matlashewski G, Schneider J, Banks L, Jones N, Murray A, Crawford L.1987. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J. 6:1741-1746.
40. Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R. 1996. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 85:1067-1076. http://dx.doi.org/10.1016/S0092-8674(00)81307-0.
41. Hirabayashi S, Tajima M, Yao I, Nishimura W, Mori H, Hata Y. 2003. JAM4, a junctional cell adhesion molecule interacting with a tight junction protein, MAGI-1. Mol. Cell. Biol. 23:4267-4282. http://dx.doi.org/10 .1128/MCB.23.12.4267-4282.2003.
42. Laura RP, Ross S, Koeppen H, Lasky LA. 2002. MAGI-1: a widely expressed, alternatively spliced tight junction protein. Exp. Cell Res. 275: 155-170. http://dx.doi.org/10.1006/excr.2002.5475.
43. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. 1986. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 103:755-766. http://dx.doi.org/10.1083/jcb.103.3.755.
44. Izumi Y, Hirose T, Tamai Y, Hirai S, Nagashima Y, Fujimoto T, Tabuse Y, Kemphues KJ, Ohno S. 1998. An atypical PKC directly associates and colocalizes at the epithelial tight junction with ASIP, a mammalian homologue of Caenorhabditis elegans polarity protein PAR-3. J. Cell Biol. 143: 95-106. http://dx.doi.org/10.1083/jcb.143.1.95.
45. Balda MS, Garrett MD, Matter K. 2003. The ZO-1-associated Y-box factorZONABregulates epithelial cell proliferation and cell density. J. Cell Biol. 160:423-432. http://dx.doi.org/10.1083/jcb.200210020.
46. Aijaz S, D'Atri F, Citi S, Balda MS, Matter K. 2005. Binding of GEF-H1 to the tight junction-associated adaptor cingulin results in inhibition of Rho signaling and G1/S phase transition. Dev. Cell 8:777-786. http://dx .doi.org/10.1016/j.devcel.2005.03.003.
47. Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, Wang Y, Ratnayaka I, Shipman M, Cheung A, Gaston-Massuet C, Ferretti P, Molnár Z, Lu X. 2010. ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev. Cell 19:126-137. http://dx.doi.org/10.1016/j.devcel.2010.06.003.
48. Balda MS, Matter K. 2000. Transmembrane proteins of tight junctions. Sem. Cell Dev. Biol. 11:281-289. http://dx.doi.org/10.1006/scdb.2000 .0177.
49. Salic A, Mitchison TJ. 2008. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 105: 2415-2420. http://dx.doi.org/10.1073/pnas.0712168105.
50. Taylor RC, Cullen SP, Martin SJ. 2008. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9:231-241. http://dx.doi.org /10.1038/nrm2312.
51. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. 1997. Major DNA fragmentation is a late event in apoptosis. J. Histochem. Cytochem. 45:923-934. http://dx.doi.org/10.1177/002215549704500702.
52. Murray D, Horgan G, Macmathuna P, Doran P. 2008. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Brit. J. Cancer 99:1322-1329. http://dx.doi .org/10.1038/sj.bjc.6604688.
53. Han X, Cheng W, Jing H, Zhang J-W, Tang L-L. 2012. Neuroepithelial transforming protein 1 short interfering RNA-mediated gene silencing with microbubble and ultrasound exposure inhibits the proliferation of hepatic carcinoma cells in vitro. J. Ultrasound Med. 31:853-861. http: //www.jultrasoundmed.org/content/31/6/853.long.
54. Ando-Akatsuka Y, Yonemura S, Itoh M, Furuse M, Tsukita S. 1999. Differential behavior of E-cadherin and occludin in their colocalization with ZO-1 during the establishment of epithelial cell polarity. J. Cell. Physiol. 179: 115-125. http://dx.doi.org/10.1002/(SICI)1097-4652(199905)179:2<115:: AID-JCP1>3.0.CO;2-T.
55. Suzuki A, Ishiyama C, Hashiba K, Shimizu M, Ebnet K, Ohno S. 2002. aPKC kinase activity is required for the asymmetric differentiation of the premature junctional complex during epithelial cell polarization. J. Cell Sci. 115:3565-3573. http://dx.doi.org/10.1242/jcs.00032.
56. Murata M, Kojima T, Yamamoto T, Go M, Takano K, Chiba H, Tokino T, Sawada N. 2005. Tight junction protein MAGI-1 is up-regulated by transfection with connexin 32 in an immortalized mouse hepatic cell line: cDNA microarray analysis. Cell Tissue Res. 319:341-347. http://dx.doi .org/10.1007/s00441-004-1017-0.
57. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, Noda T, Tsukita S. 2000. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 11:4131-4142. http: //dx.doi.org/10.1091/mbc.11.12.4131.
58. Bordin M, D'Atri F, Guillemot L, Citi S. 2004. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. Mol. Cancer Res. 2:692-701. http://mcr.aacrjournals.org/content/2/12/692.long.
59. Li D, Mrsny RJ. 2000. Oncogenic Raf-1 disrupts epithelial tight junctions via downregulation of occludin. J. Cell Biol. 148:791-800. http://dx.doi .org/10.1083/jcb.148.4.791.
60. Mino A, Ohtsuka T, Inoue E, Takai Y. 2000. Membrane-associated guanylate kinase with inverted orientation (MAGI)-1/brain angiogenesis inhibitor 1-associated protein (BAP1) as a scaffolding molecule for Rap small G protein GDP/GTP exchange protein at tight junctions. Genes Cells 5:1009-1016. http://dx.doi.org/10.1046/j.1365-2443.2000.00385.x.
61. Sakurai A, Fukuhara S, Yamagishi A, Sako K, Kamioka Y, Masuda M, Nakaoka Y, Mochizuki N. 2006. MAGI-1 is required for Rap1 activation upon cell-cell contact and for enhancement of vascular endothelial cadherin-mediated cell adhesion. Mol. Biol. Cell 17:966-976. http://dx.doi .org/10.1091/mbc.E05-07-0647.
62. Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P. 2006. Net1 and Myeov: computationally identified mediators of gastric cancer. Brit. J. Cancer 94:1204-1212. http://dx.doi.org/10.1038/sj.bjc.6603054.
63. Dubash AD, Guilluy C, Srougi MC, Boulter E, Burridge K, García-Mata R. 2011. The small GTPase RhoA localizes to the nucleus and is activated by Net1 and DNA damage signals. PLoS One 6:e17380. http://dx.doi.org /10.1371/journal.pone.0017380.